Pfizer expects $15bn in Covid vaccine revenue this year | Financial Times

Shares in Pfizer, which are trading roughly where they were before the pandemic, fell 3 per cent to $34.88. Mr Bourla said he did not think the company’s stock was receiving enough “credit” for its underlying business or for the prospects of the Covid-19 vaccine.

Source: Pfizer expects $15bn in Covid vaccine revenue this year | Financial Times

Source: Pfizer expects $15bn in Covid vaccine revenue this year | Financial Times